Literature DB >> 6198081

Biologicals and biological response modifiers: fourth modality of cancer treatment.

R K Oldham.   

Abstract

Considerable progress has been made in the last 5 years toward the development of specific biological approaches to the treatment of cancer. The techniques of genetic engineering, mass cell culture, and improved techniques in protein and nucleic acid sequencing and synthesis have made available biologicals as specific, highly purified molecules that can be used in cancer therapy. While extensive clinical trials are needed to demonstrate that biologicals and biological response modifiers can provide a survival advantage for patients with cancer, the preliminary data indicate that these approaches can be useful in inducing responses in patients with clinically apparent disease. Further studies with these approaches in conjunction with surgery, radiotherapy, and chemotherapy should be helpful in definitively establishing biologicals and biological response modifiers as the fourth modality of cancer treatment.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6198081

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  7 in total

1.  Preliminary result of mixed bacterial vaccine as adjuvant treatment of hepatocellular carcinoma.

Authors:  Z Y Tang; H Y Zhou; G Zhao; L M Chai; M Zhou; J Z Lu; K D Liu; H F Havas; H C Nauts
Journal:  Med Oncol Tumor Pharmacother       Date:  1991

Review 2.  Immunoconjugates: applications in targeted drug delivery for cancer therapy.

Authors:  B P Ram; P Tyle
Journal:  Pharm Res       Date:  1987-06       Impact factor: 4.200

3.  Effect of interleukin-2 on the manifestation and growth of acetoxymethyl-methylnitrosamine-induced colorectal rat adenocarcinoma.

Authors:  F T Garzon; M Salas; M R Berger; H Kirchner
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

4.  Human anti-(murine Ig) antibody responses in patients with hepatocellular carcinoma receiving intrahepatic arterial 131I-labeled Hepama-1 mAb. Preliminary results and discussion.

Authors:  Z C Zeng; Z Y Tang; K D Liu; J Z Lu; X J Cai; H Xie
Journal:  Cancer Immunol Immunother       Date:  1994-11       Impact factor: 6.968

5.  Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors.

Authors:  Noboru Yamamoto; Hiroshi Nokihara; Yasuhide Yamada; Takashi Shibata; Yosuke Tamura; Yoshitaka Seki; Kazunori Honda; Yuko Tanabe; Hiroshi Wakui; Tomohide Tamura
Journal:  Invest New Drugs       Date:  2016-12-08       Impact factor: 3.850

Review 6.  Trichinella spiralis and Tumors: Cause, Coincidence or Treatment?

Authors:  Chengshui Liao; Xiangchao Cheng; Mingyuan Liu; Xuelin Wang; Pascal Boireau
Journal:  Anticancer Agents Med Chem       Date:  2018       Impact factor: 2.505

7.  Antiproliferative activity of the isofuranonaphthoquinone isolated from Bulbine frutescens against Jurkat T cells.

Authors:  Penelope Tambama; Berhanu Abegaz; Stanley Mukanganyama
Journal:  Biomed Res Int       Date:  2014-01-16       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.